Human BCMA Protein, ECD (Extracellular Domain), Fc-fusion, Recombinant

Description

BCMA (B cell maturation antigen), is a single-pass, type III transmembrane glycoprotein in the TNF receptor superfamily (TNFRSF17). BCMA contains a short extracellular domain (ECD) of 84 amino acid (aa), containing one TNFR cysteine-rich repeat. Within the TNFRSF, it shares the highest homology with TACI (TNFRSF13B). Both BCMA and TACI have been shown to bind to APRIL (TNFSF13) and BAFF (TNFSF13B), members of the TNF ligand superfamily. BCMA is expressed in immune organs and mature B cells, but not in T-cells or monocytes. BCMA is located on the cell surface and also found in a perinulear Golgi-like structure.  The binding of BCMA to APRIL or BAFF has been shown to stimulate IgM production in peripheral blood B cells and increase the survival of B cells, suggesting that BCMA may play an important role in B cell development,  function and regulation. BCMA lacks a death domain (DD) in the cystoplasmic region.  BCMA interacts with various TNFR-associated factors (TRAFs), including TRAF1, TRAF2 and TRAF3, to transduce signals for B cell survival and proliferation. Overexpression of BCMA activates NF-κB and JNK signaling pathways. A chromosomal aberration in BCMA is found in a form of T-cell acute lymphoblastic leukemia (T-ALL).

  

 

Gene Symbol: TNFRSF17; CD269; BCM; TNFRSF13A

 

NCBI Gene ID: 608

 

Uniprot Entry: Q02223

 

Construct Details: The recombinant human BCMA-Fc fusion is expressed as a 281 amino acid protein consisting of Leu2 - Ala54 region of BCMA (UniProt accession #Q02223) and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions (see the gel image inserted above).  

   

Source: Human cells stably expressing human BCMA-Fc and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence: 

        10         20         30         40         50         60 

LQMAGQCSQN EYFDSLLHAC IPCQLRCSSN TPPLTCQRYC NASVTNSVKG TNASTGTHTC 

        70         80         90        100        110        120 

PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN 

       130        140        150        160        170        180 

AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 

       190        200        210        220        230        240 

QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL  

       250        260        270        280 

YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K

 

M.W.: Calculated molecular mass (kDa): 31.3; Estimated by SDS-PAGE under reducing condition (kDa): ~45

 

Calculated PI: 7.63

 

Calculated extinction coefficients (M-1 cm-1, at 280nm): 39140

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "DTT: +")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free).

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds to its ligand APRIL and BAFF.  Inhibits APRIL-­ and BAFF-mediated signaling activities including NF-κB activation and proliferation of anti­-IgM co-stimulated B cells. 

 

 

  

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

 

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

 

1. J Immunol. 165:1322 (2000).

2. Immunol Res.26: 323 (2002). 

3. J. Exp. Med. 192:129 (2000).

4. Nature 404:995 (2000).

5. Nat. Immunol. 1:252 (2000).

 

 

 

 

 

Product datasheet (pdf) can be downloaded here: FCL0106-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.